Fusion Antibodies Plc

As of March 31, 2026, Fusion Antibodies Plc carries a market capitalization of 1.56B, placing it among publicly traded companies globally. Its enterprise value stands at 1.49B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Fusion Antibodies Plc's next confirmed earnings release is scheduled for December 7, 2026.

As of March 31, 2026, Fusion Antibodies Plc has 125.02M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Fusion Antibodies Plc maintains a current ratio of 2.82, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities.

As of the close on October 22, 2026, Fusion Antibodies Plc's stock has declined approximately 60.34% over the past 52 weeks. The 50-day moving average sits at 10.39, while the 200-day moving average is 12.25.

As of March 31, 2026, Fusion Antibodies Plc holds 104.30M in cash and equivalents against 33.10M in total debt, resulting in a net debt position of -104.30M. Total book value stands at 162.20M, with working capital of 152.90M providing operational flexibility.